Fig. 8.

P4HA1 expression is associated with chemoresistance and activation of the HIF-1 gene signature. a, b Growth of patient-derived tumor organoids (PDOs) in the 3D laminin-rich ECM gel was assessed after docetaxel (DOC), doxorubicin (DOX), and/or P4HA inhibitor (DHB) treatment; results are presented as mean ± SEM. n = 89; **p < 0.01, one-way ANOVA test. Bar, 40 µm. c Tumor growth curve of PDX treated with DHB (40 mg/kg) and/or DOC (10 mg/kg); n = 5; **p < 0.01; *p < 0.05, one-way ANOVA test. d The association of P4HA1 expression with recurrence-free survival was assessed by analyzing the mRNA levels in basal-like/TNBC tissues, n = 580, Kaplan–Meier survival analysis. e The association of P4HA1 expression with recurrence-free survival was assessed by analyzing the mRNA levels in basal-like/TNBC tissues from patient received adjuvant and neoadjuvant chemotherapy, n = 128, Kaplan–Meier survival analysis. f Heatmap and Box plot showed the association of P4HA1 levels and expression of the HIF-1 gene signature in human breast cancer tissue. The median, 10th, 25th, 75th, and 90th percentiles were plotted as vertical boxes with error bars, n = 39, **p < 0.01, one-way ANOVA test